Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Jackisch · SciRah

Researcher profile · Semantic Scholar

C. Jackisch

Share profile

C. Jackisch — researcher profile on SciRah

h-index: 83
Works: 589
Citations: 38K

Most-cited papers

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
C. Denkert, F. Seither, A. Schneeweiss, T. Link +30 more
2021The Lancet Oncology451 citations
Semantic Scholar
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
L. Cortesi, H. Rugo, C. Jackisch
2021Targeted oncology331 citations Open access
Semantic Scholar
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
S. Loibl, A. Schneeweiss, J. Huober, M. Braun +15 more
2022Annals of Oncology238 citations Open access
Semantic Scholar
Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
M. Pegram, C. Jackisch, S. Johnston
2023npj Breast Cancer136 citations Open access
Semantic Scholar
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
P. Fasching, T. Link, J. Hauke, F. Seither +20 more
2020Annals of Oncology135 citations Open access
Semantic Scholar
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
S. Loibl, A. Schneeweiss, J. Huober, M. Braun +15 more
2021Journal of Clinical Oncology94 citations
Semantic Scholar
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
S. Villegas, V. Nekljudova, N. Pfarr, J. Engel +26 more
2021European Journal of Cancer80 citations
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2020.
N. Ditsch, M. Untch, C. Kolberg-Liedtke, C. Jackisch +42 more
2020Breast Care78 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022
N. Ditsch, Achim Wöcke, M. Untch, C. Jackisch +42 more
2022Breast Care76 citations Open access
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021
N. Ditsch, C. Kolberg-Liedtke, Michael Friedrich, C. Jackisch +42 more
2021Breast Care76 citations Open access
Semantic Scholar
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer
M. V. van Mackelenbergh, S. Loibl, M. Untch, M. Buyse +25 more
2023Journal of Clinical Oncology71 citations
Semantic Scholar
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy
P. Squifflet, E. Saad, S. Loibl, M. V. van Mackelenbergh +25 more
2023Journal of Clinical Oncology40 citations
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021
M. Thill, Michael Friedrich, C. Kolberg-Liedtke, U. Albert +42 more
2021Breast Care38 citations Open access
Semantic Scholar
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
J. Huober, M. V. van Mackelenbergh, A. Schneeweiss, F. Seither +16 more
2023npj Breast Cancer35 citations Open access
Semantic Scholar
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast
A. Schneeweiss, L. Michel, Volker Möbus, H. Tesch +18 more
2021European Journal of Cancer35 citations
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023
M. Thill, C. Kolberg-Liedtke, U. Albert, M. Banys-Paluchowski +43 more
2023Breast Care32 citations Open access
Semantic Scholar
Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients with Ovarian Cancer.
K. Weber-Lassalle, C. Ernst, A. Reuss, K. Möllenhoff +18 more
2021Journal of the National Cancer Institute32 citations Open access
Semantic Scholar
58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment
F. Marmé, C. Hanusch, J. Furlanetto, P. Morris +16 more
2022Annals of Oncology30 citations Open access
Semantic Scholar
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis
S. Swain, H. Macharia, J. Cortés, C. Dang +11 more
2022Cancers29 citations Open access
Semantic Scholar
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
B. Gerber, A. Schneeweiss, V. Möbus, M. Golatta +21 more
2022Cancers29 citations Open access
Semantic Scholar
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial
J. Pfisterer, F. Joly, G. Kristensen, J. Rau +26 more
2022Journal of Clinical Oncology29 citations Open access
Semantic Scholar
AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update
M. Friedrich, T. Kühn, W. Janni, V. Müller +44 more
2021Geburtshilfe und Frauenheilkunde26 citations Open access
Semantic Scholar
AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022
M. Banys-Paluchowski, M. Thill, T. Kühn, N. Ditsch +42 more
2022Geburtshilfe und Frauenheilkunde24 citations Open access
Semantic Scholar
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge.
C. Jackisch, P. Cortazar, C. Geyer, L. Gianni +8 more
2021Cancer Treatment Reviews23 citations Open access
Semantic Scholar
White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
C. Jackisch, Federico Manevy, S. Frank, N. Roberts +1 more
2022Advances in Therapy22 citations Open access
Semantic Scholar
Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023
T. Park-Simon, V. Müller, C. Jackisch, U. Albert +43 more
2023Breast Care21 citations Open access
Semantic Scholar
Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2).
V. Möbus, H. Lück, E. Ladda, P. Klare +23 more
2021European Journal of Cancer19 citations
Semantic Scholar
Updated results from the international phase III ALTTO trial (BIG 2–06/Alliance N063D)
A. Moreno-Aspitia, E. Holmes, C. Jackisch, E. de Azambuja +25 more
2021European Journal of Cancer18 citations Open access
Semantic Scholar
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
J. Blohmer, T. Link, M. Reinisch, M. Just +17 more
2022JAMA Oncology16 citations Open access
Semantic Scholar
Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy.
J. Furlanetto, V. Möbus, A. Schneeweiss, K. Rhiem +20 more
2021European Journal of Cancer16 citations
Semantic Scholar
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.
C. Denkert, M. Untch, S. Benz, A. Schneeweiss +24 more
2021Annals of Oncology16 citations Open access
Semantic Scholar
Utility of the CPS + EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy.
F. Marmé, C. Solbach, L. Michel, A. Schneeweiss +14 more
2021European Journal of Cancer15 citations
Semantic Scholar
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022
M. Thill, D. Lüftner, C. Kolberg-Liedtke, U. Albert +42 more
2022Breast Care13 citations Open access
Semantic Scholar
Update Breast Cancer 2021 Part 1 – Prevention and Early Stages
E. Stickeler, B. Aktas, A. Behrens, E. Belleville +23 more
2021Geburtshilfe und Frauenheilkunde13 citations Open access
Semantic Scholar
Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
C. Jackisch, C. Barcenas, R. Bartsch, J. Dipalma +7 more
2021Clinical Breast Cancer12 citations Open access
Semantic Scholar
[New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis].
C. Denkert, A. Lebeau, H. Schildhaus, C. Jackisch +1 more
2022Pathologie10 citations Open access
Semantic Scholar
AGO Algorithms for the Treatment of Breast Cancer: Update 2021
A. Schneeweiss, P. Fasching, T. Fehm, B. Gerber +7 more
2021Geburtshilfe und Frauenheilkunde10 citations Open access
Semantic Scholar
The Effect of Collaborative Reviews of Electronic Patient-Reported Outcomes on the Congruence of Patient- and Clinician-Reported Toxicity in Cancer Patients Receiving Systemic Therapy: Prospective, Multicenter, Observational Clinical Trial
A. Trojan, Nicolas Leuthold, C. Thomssen, A. Rody +5 more
2021Journal of Medical Internet Research10 citations Open access
Semantic Scholar
ABC6 Consensus: Assessment by a Group of German Experts
D. Lüftner, P. Fasching, R. Haidinger, N. Harbeck +6 more
2022Breast Care9 citations Open access
Semantic Scholar
Is weight-based IV dosing of trastuzumab preferable to SC fixed-dose in some patients? A systematic scoping review
H. Kolberg, C. Jackisch, S. Hurvitz, J. Winstone +3 more
2021Breast9 citations Open access
Semantic Scholar
Treatment of Early Breast Cancer
M. Untch, M. Banys-Paluchowski, S. Brucker, W. Budach +18 more
2023Geburtshilfe und Frauenheilkunde8 citations Open access
Semantic Scholar
Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial
P. Fasching, Christopher W. Szeto, C. Denkert, S. Benz +20 more
2023Clinical Cancer Research8 citations Open access
Semantic Scholar
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer
J. Bines, E. Clark, C. Barton, E. Restuccia +13 more
2021British Journal of Cancer8 citations Open access
Semantic Scholar
Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus
M. Untch, P. Fasching, S. Brucker, W. Budach +15 more
2021Geburtshilfe und Frauenheilkunde8 citations Open access
Semantic Scholar
199TiP Phase III post-neoadjuvant study evaluating sacituzumab govitecan (SG), an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA
F. Marmé, C. Hanusch, J. Furlanetto, C. Denkert +12 more
2021Annals of Oncology8 citations Open access
Semantic Scholar
Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
N. Ditsch, E. Stickeler, A. Behrens, E. Belleville +23 more
2021Geburtshilfe und Frauenheilkunde7 citations Open access
Semantic Scholar
RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial.
T. Link, J. Blohmer, W. Schmitt, J. Kuhlmann +17 more
2023Clinical Cancer Research6 citations
Semantic Scholar
Caveolin gene expression predicts clinical outcomes for early-stage HER2-negative breast cancer treated with paclitaxel-based chemotherapy in the GeparSepto trial
Terence M. Williams, A. Schneeweiss, C. Jackisch, Changxian Shen +18 more
2023Clinical Cancer Research6 citations Open access
Semantic Scholar
Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer.
T. Karn, C. Denkert, J. Rey, K. Weber +14 more
2022Journal of Clinical Oncology6 citations
Semantic Scholar
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study
M. Reinisch, M. Untch, R. Mahlberg, T. Reimer +21 more
2022Breast6 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Untch×33
Invite
M. Untch — researcher profile on SciRah
A. Schneeweiss×32
Invite
A. Schneeweiss — researcher profile on SciRah
S. Loibl×27
Invite
S. Loibl — researcher profile on SciRah
J. Huober×26
Invite
J. Huober — researcher profile on SciRah

×21

Invite

P. Fasching — researcher profile on SciRah

E. Stickeler×19

Invite

E. Stickeler — researcher profile on SciRah

Invite

K. Rhiem — researcher profile on SciRah

Invite

W. Janni — researcher profile on SciRah

Invite

C. Denkert — researcher profile on SciRah

Invite

C. Solbach — researcher profile on SciRah

V. Nekljudova×15

Invite

V. Nekljudova — researcher profile on SciRah

Invite

V. Müller — researcher profile on SciRah